http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2764767-C2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_361c6223f33de77431dc880348294a7c |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-207 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-16 |
| filingDate | 2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_434d98a1ceff3eab095884b141893a7e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_575ae645b209afd6ef29f8d5166d1981 |
| publicationDate | 2022-01-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2764767-C2 |
| titleOfInvention | β-D-2ʹ-DEOXY-2ʹ-α-FLUORO-2ʹ-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR TREATMENT OF DISEASES CAUSED BY HCV |
| abstract | FIELD: medicine.SUBSTANCE: present invention relates to a compound selected from compounds of formulas:,,, or to its pharmaceutically acceptable salt, to a compound of the formula:or to its pharmaceutically acceptable salt, where the compound is at least 90% free of opposite R-enantiomer for phosphorus, to a compound of the formula:or to its pharmaceutically acceptable salt, where the compound is at least 90% free of opposite S-enantiomer for phosphorus, to pharmaceutical compositions containing these compounds, to methods for the therapeutic treatment of HCV in a host using these compounds, as well as to the use of these compounds for the treatment of HCV in a host and in the production of a drug for the treatment of HCV in a host.EFFECT: obtaining compounds for the treatment of HCV.31 cl, 11 dwg, 7 tbl, 34 ex |
| priorityDate | 2015-03-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 498.